Assessing consistency across functional screening datasets in cancer cells

Abstract Motivation Many high-throughput screening studies have been carried out in cancer cell lines to identify therapeutic agents and targets. Existing consistency assessment studies only examined two datasets at a time, with conclusions based on a subset of carefully selected features rather than considering global consistency of all the data. However, poor concordance can still be observed for a large part of the data even when selected features are highly consistent. Results In this study, we assembled nine compound screening datasets and three functional genomics datasets. We derived direct measures of consistency as well as indirect measures of consistency based on association between functional data and copy number-adjusted gene expression data. These results have been integrated into a web application—the Functional Data Consistency Explorer (FDCE), to allow users to make queries and generate interactive visualizations so that functional data consistency can be assessed for individual features of interest. Availability and implementation The FDCE web tool and we have developed and the functional data consistency measures we have generated are available at https://lccl.shinyapps.io/FDCE/. Supplementary information Supplementary data are available at Bioinformatics online.

[1]  Kevin R. Coombes,et al.  The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data , 2009, Cancer informatics.

[2]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Kristina Hanspers,et al.  Gene expression profiles during human CD4+ T cell differentiation. , 2004, International immunology.

[4]  B. Faubert,et al.  Metabolic diversity in human non-small cell lung cancer , 2014, bioRxiv.

[5]  A. Monks,et al.  Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. , 2016, Journal of the National Cancer Institute.

[6]  R. Deberardinis,et al.  Genomic regression analysis of coordinated expression , 2017, Nature Communications.

[7]  D. Morgens,et al.  Systematic comparison of CRISPR-Cas9 and RNAi screens for essential genes , 2016, Nature Biotechnology.

[8]  Michael P. Morrissey,et al.  Pharmacogenomic agreement between two cancer cell line data sets , 2015, Nature.

[9]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[10]  Henry E. Kyburg,et al.  Comparison of Approaches , 1974 .

[11]  Michael Peyton,et al.  Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer , 2018, Cell.

[12]  Amos Bairoch,et al.  The Cellosaurus, a Cell-Line Knowledge Resource. , 2018, Journal of biomolecular techniques : JBT.

[13]  A. Lin,et al.  Discovering and validating cancer genetic dependencies: approaches and pitfalls , 2020, Nature Reviews Genetics.

[14]  C. Cole,et al.  The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers , 2018, Nature Reviews Cancer.

[15]  Benjamin Haibe-Kains,et al.  Inconsistency in large pharmacogenomic studies , 2013, Nature.

[16]  Luc Girard,et al.  Lung cancer cell lines as tools for biomedical discovery and research. , 2010, Journal of the National Cancer Institute.

[17]  K. Kohn,et al.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.

[18]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[19]  P. Meltzer,et al.  SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures , 2020, Cell reports.

[20]  Joshua M. Korn,et al.  Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.

[21]  Robert Preissner,et al.  WITHDRAWN—a resource for withdrawn and discontinued drugs , 2015, Nucleic Acids Res..

[22]  Aviad Tsherniak,et al.  Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration , 2018, Nature Communications.

[23]  Scott E. Martin,et al.  Reproducible pharmacogenomic profiling of cancer cell line panels , 2016, Nature.

[24]  Joshua A. Bittker,et al.  Discovering the anticancer potential of non-oncology drugs by systematic viability profiling , 2020, Nature Cancer.

[25]  Leopold Parts,et al.  Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets , 2019, Nature Communications.

[26]  Joshua C. Gilbert,et al.  An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.

[27]  Emanuel J. V. Gonçalves,et al.  Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening , 2019, Nature Communications.

[28]  Joshua A. Bittker,et al.  Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.

[29]  Genomics of Drug Sensitivity in Cancer , 2020, Definitions.

[30]  Robert Clarke,et al.  Enhancing reproducibility in cancer drug screening: how do we move forward? , 2014, Cancer research.

[31]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[32]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Foisner,et al.  The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity , 2007, Oncogene.

[34]  Joshua A. Bittker,et al.  Correlating chemical sensitivity and basal gene expression reveals mechanism of action , 2015, Nature chemical biology.

[35]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[36]  Benjamin Haibe-Kains,et al.  Assessment of pharmacogenomic agreement , 2016, bioRxiv.